Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 21;2015(7):CD011437.
doi: 10.1002/14651858.CD011437.pub2.

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma

David J W Evans  1 , Kayleigh M Kew, Debbie E Anderson, Anne C Boyter
Affiliations

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma

David J W Evans et al. Cochrane Database Syst Rev. .

Abstract

Background: Long-acting muscarinic antagonists (LAMA), a class of drugs with proven effectiveness in chronic obstructive pulmonary disease (COPD), are being considered as an add-on option for adults with asthma whose condition is uncontrolled on inhaled corticosteroids (ICS). It is important to assess the safety and efficacy of LAMA add-on as an alternative to the prolonged use of higher doses of ICS, which are known to cause undesirable side effects in some people.

Objectives: To compare the effects of adding a LAMA to any dose of ICS versus increasing the dose of ICS, for uncontrolled asthma in adults.

Search methods: We searched the Cochrane Airways Group Specialised Register (CAGR) from its inception in 1995 to April 2015, imposing no restriction on language of publication. We also handsearched trial registries, reference lists of primary studies and existing reviews, as well as manufacturers' websites.

Selection criteria: We looked for parallel or cross-over randomised controlled trials lasting at least 12 weeks, in which adults whose asthma was not well controlled on ICS alone were randomised to treatment with LAMA add-on to ICS or with an increased dose of ICS. Trials were excluded if patients were taking long-acting beta2-agonists during the study period.

Data collection and analysis: Two review authors independently screened the searches and extracted data from studies meeting all the inclusion criteria. We used Covidence to manage duplicate screening, data extraction and risk of bias judgements, and to form a consensus where discrepancies arose. We used standard methods expected by The Cochrane Collaboration.The pre-specified primary outcomes were exacerbations requiring a course of oral corticosteroids (OCS), effects on quality of life and serious adverse events.

Main results: One cross-over randomised controlled trial met the inclusion criteria. The trial was performed in 210 patients with moderate to severe asthma and compared the use of the LAMA tiotropium bromide with double dose beclomethasone (an ICS) using a cross-over design and 14-week treatment periods.Compared with people taking a double dose of ICS, fewer people taking a LAMA add-on had an exacerbation requiring treatment with OCS (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.22 to 1.43) or an exacerbation resulting in emergency department admission (OR 0.49, 95% CI 0.09 to 2.77), but the confidence intervals for both outcomes did not exclude the possibility that double dose ICS was more effective. Serious adverse events and exacerbations requiring hospitalisation occurred in similarly low numbers of people taking each treatment, but confidence intervals were too wide to suggest that the two treatment options were equivalent.Asthma-related quality of life was similar in both treatment groups (mean difference (MD) in change from baseline 0.10, 95% CI - 0.07 to 0.27). Those taking LAMA add-on scored slightly better on a scale measuring asthma control than those increasing their ICS dose (MD in change from baseline - 0.18, 95% CI - 0.34 to - 0.02), although the difference was clinically small. Evidence was deemed low quality for both quality of life and asthma control.There was moderate-quality evidence that participants' trough forced expiratory volume in one second (FEV1) was 100 mL better when taking LAMA add-on than with increased ICS dose (MD in change from baseline 0.10, 95% CI 0.03 to 0.17).

Authors' conclusions: Only one randomised trial was found, comparing tiotropium add-on to increased dose beclomethasone. Differences between the treatments were too small or imprecise to understand whether adding a LAMA to ICS is safer or more effective than increasing the dose of ICS, and there is a possibility of carry-over effects due to the study's cross-over design. LAMA add-on may lead to more improvement in lung function (FEV1) than an increased dose of ICS.The results of this review, alongside pending results from related reviews assessing the use of LAMA against other treatments, will help to define the role of these drugs in asthma management, and this review should be updated as results from future trials emerge. Studies assessing the role of LAMA add-on should be longer and include a double-ICS treatment arm so that the results can be interpreted in the context of the guideline-recommended treatment options that are available to physicians.

PubMed Disclaimer

Conflict of interest statement

Kayleigh Kew: none known

Debbie Allison: none known

Anne Boyter: none known

David Evans: none known

Figures

1
1
Study flow diagram
1.1
1.1. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 1 Exacerbations requiring a course of OCS.
1.2
1.2. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 2 Asthma QoL questionnaire score.
1.3
1.3. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 3 SAEs (all cause).
1.4
1.4. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 4 Exacerbations (hospital).
1.5
1.5. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 5 Exacerbations (ED).
1.6
1.6. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 6 FEV1 pre‐albuterol (L).
1.7
1.7. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 7 FEV1 post‐albuterol (L).
1.8
1.8. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 8 Morning PEF (L/min).
1.9
1.9. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 9 Evening PEF (L/min).
1.10
1.10. Analysis
Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 10 Asthma Control Questionnaire score.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Peters 2010 {published and unpublished data}
    1. Lane M. Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh 2010;40(4):321‐2. - PubMed
    1. NCT00565266. Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015).
    1. Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology 2013;132(5):1068‐74. - PMC - PubMed
    1. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine 2010;363(18):1715‐26. - PMC - PubMed

References to studies excluded from this review

Beeh 2013 {published data only}
    1. Beeh KM, Ablinger O, Moroni‐Zentgraf P, Hollaenderova Z, Pivovarova A, Engel M, et al. Once‐daily add‐on tiotropium: A dose‐finding trial in adult patients with moderate persistent asthma [Abstract]. Allergy 2013;68(s97):376‐7.
Bernstein 2013 {published data only}
    1. Bernstein JA, Kerstjens HAM, Moroni‐Zentgraf P, Engel M, Schmidt H, Halpin DMG. Once‐daily tiotropium is well tolerated as add‐on to standard treatment for patients with symptomatic asthma despite receiving inhaled corticosteroids and long‐acting beta2‐agonists [Abstract]. Chest 2013;144(4 Meeting Abstracts):89A.
Casale 2014 {published data only}
    1. Casale TB, Bateman ED, Dahl R, Pizzichini E, Vandewalker ML, Virchow JC, et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of TH2 inflammatory status [Abstract]. The Journal of Allergy and Clinical Immunology 2014;133(2 Suppl):AB5.
    1. Casale TB, Bleecker ER, Meltzer E, Pizzichini E, Schmidt O, Bateman ED, et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses [Abstract]. Allergy 2013;68(Suppl 97):377.
Corren 2014 {published data only}
    1. Corren J, Murphy KR, Bensch G, Dahl R, Paggiaro P, Engel M, et al. Once‐daily tiotropium respimat decreases the risk of exacerbations, independent of baseline characteristics, in patients with symptomatic severe asthma without evidence of chronic obstructive pulmonary disease. Journal of General Internal Medicine 2014;29:S157‐8.
CTRI/2008/091/000306 {published data only}
    1. CTRI/2008/091/000306. A randomized, double‐blind, crossover, non‐inferiority study comparing bronchodilator effects of single dose of 18 mcg of Tiotropium Bromide and two doses of 12 mcg of formoterol fumarate each over 24 hours in subjects with moderate to severe asthma. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=284&E... (accessed 19 January 2015).
CTRI/2012/08/002915 {published data only}
    1. CTRI/2012/08/002915. Assessment of various second line treatment regimens on mild to moderate persistent asthmatic patients. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5059&... (accessed 19 January 2015).
Dahl 2014a {published data only}
    1. Dahl R, Doherty DE, Corren J, Karpel J, Kerstjens HAM, Engel M, et al. Once‐daily tiotropium respimat improves lung function in patients with severe symptomatic asthma independent of leukotriene modifier use [Abstract]. The Journal of Allergy and Clinical Immunology 2014;133(2 Suppl):AB5.
Dahl 2014b {published data only}
    1. Dahl R, Bateman ED, Casale TB, Pizzichini E, Vandewalker M, Virchow JC, et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status [Abstract]. 33rd Congress of the European Academy of Allergy and Clinical Immunology; 2014 June 7‐11; Copenhagen. 2014.
Doherty 2013 {published data only}
    1. Doherty DE, Tashkin DP, Harrison TW, Engel M, Schmidt H, Moroni‐Zentgraf P, et al. Improvements in lung function with tiotropium as add‐on controller therapy to ICS+LABA for patients with symptomatic severe asthma [Abstract]. Chest 2013;144(4 Meeting Abstracts):88A.
EUCTR2006‐003385‐34‐NL {published data only}
    1. EUCTR2006‐003385‐34‐NL. The effect of tiotropium‐bromide on deep inspiration‐induced bronchodilation and airway responsiveness in asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐003385‐34/NL/#A (accessed 19 January 2015).
Haggart 2004 {published data only}
    1. Haggart K, Fardon TC, Lee DKC, Lipworth BJ. Stepping down inhaled steroids in severe asthma with long acting bronchodilators: utilising effort dependent and independent measures of pulmonary function [Abstract]. Thorax 2004;59(Suppl 2):ii72.
Halpin 2010 {published data only}
    1. Halpin DMG, Bateman ED, Tashkin DP, Engel M, Dahl R, Paggiaro P, et al. Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics including markers of allergic status [Abstract]. Thorax 2013;68(Suppl 3):A149.
Howaza 2013 {published data only}
    1. Hozawa S, Kerstjens HAM, Tashkin DP, Engel M, Ronald D, Paggiaro P, et al. Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics [Abstract]. Respirology 2013;18(S4):175.
JPRN‐UMIN000010352 {published data only}
    1. JPRN‐UMIN000010352. Study for effects of tiotropium on smokers and non‐smokers with bronchial asthma. http://www.umin.ac.jp/ctr/index.htm (accessed 19 January 2015).
Kerstjens 2012 {published data only}
    1. Corren J, Frew A, Engel M, Schmidt H, Moroni‐Zentgraf P, Kerstjens HAM. Tiotropium as add‐on therapy to ICS+LABA in patients with symptomatic severe asthma: spirometric assessment over 24 hours [Abstract]. Chest 2013;144(4 Meeting Abstracts):91A.
    1. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. New England Journal of Medicine 2012;367(13):1198‐207. - PubMed
    1. Vandewalker ML, Engel M, Schmidt H, Siebold W, Moroni‐Zentgraf P, Kerstjens HAM, et al. Efficacy of tiotropium in patients with asthma in relation to allergic status [Abstract]. The Journal of Allergy and Clinical Immunology 2013;131(2 Suppl 1):AB1.
NCT00350207 {published data only}
    1. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. The Journal of Allergy and Clinical Immunology 2011;128(2):315‐22. - PubMed
    1. NCT00350207. A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://clinicaltrials.gov/show/NCT00350207 (accessed 19 January 2015).
NCT00557180 {published data only}
    1. NCT00557180. Obesity, Inflammation and Response to Therapy in Asthma ‐ Ancillary to Asthma Clinical Research Network (ACRN) Trials. https://clinicaltrials.gov/ct2/show/NCT00557180 (accessed 19 January 2015).
NCT00706446 {published data only}
    1. NCT00706446. Genotype stratified treatment with anticholinergic vs. beta‐agonist (long acting) and exacerbations (GABLE). http://clinicaltrials.gov/show/NCT00706446 (accessed 19 January 2015).
NCT01172808 {published data only}
    1. NCT01172808. A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 weeks in moderate persistent asthma. http://clinicaltrials.gov/show/NCT01172808 (accessed 19 January 2015).
NCT01172821 {published data only}
    1. NCT01172821. A Phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg Twice Daily) over 24 weeks in moderate persistent asthma. http://clinicaltrials.gov/show/NCT01172821 (accessed 19 January 2015).
NCT01290874 {published data only}
    1. NCT01290874. Blacks and Exacerbations on LABA vs. Tiotropium (BELT). http://clinicaltrials.gov/show/NCT01290874 (accessed 19 January 2015).
NCT01316380 {published data only}
    1. NCT01316380. A Phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 ug and 5 ug once daily) compared to placebo over 12 weeks in mild persistent asthma. http://clinicaltrials.gov/show/NCT01316380 (accessed 19 January 2015).
NCT01340209 {published data only}
    1. NCT01340209. A Phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg Once Daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://clinicaltrials.gov/show/NCT01340209 (accessed 19 January 2015).
NCT01573624 {published data only}
    1. NCT01573624. A multi‐center, randomized, double‐blind, dose‐ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma. http://clinicaltrials.gov/show/NCT01573624 (accessed 19 January 2015).
NCT01641692 {published data only}
    1. NCT01641692. A multi‐national, randomized, double‐blind, placebo‐controlled, 3‐period crossover study with GSK 573719 as monotherapy in adult subjects with asthma. http://clinicaltrials.gov/show/NCT01641692 (accessed 19 January 2015).
NCT01696214 {published data only}
    1. NCT01696214. SAPS: smoking asthmatics pilot study. http://clinicaltrials.gov/show/NCT01696214 (accessed 19 January 2015).
NCT02127697 {published data only}
    1. NCT02127697. A randomized, double‐blind, parallel group, 52‐week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma. http://clinicaltrials.gov/show/NCT02127697 (accessed 19 January 2015).
Paggiaro 2013 {published data only}
    1. Paggiaro P, Engel M, Tudoric N, Forstner B, Radeczky E, Zubek V, et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses [Abstract]. European Respiratory Journal 2013;42(Suppl 57):877s [P4133].
Paggiaro 2014 {published data only}
    1. Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek V, Blahova Z, et al. Tiotropium respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: Results from a phase III trial. The Journal of Allergy and Clinical Immunology 2014;133(2 Suppl):AB4.
Rajanandh 2014a {published data only}
    1. Rajanandh MG, Nageswari AD, Ilango K. Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized controlled trial. Clinical and Experimental Pharmacology and Physiology 2014;41(7):509‐13. - PubMed
Rajanandh 2014b {published data only}
    1. Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clinical Therapeutics 2014;36(4):526‐33. - PubMed
Tashkin 2013 {published data only}
    1. Tashkin DP, Moroni‐Zentgraf P, Engel M, Schmidt H, Kerstjens HAM. Once‐daily tiotropium reduces risk of exacerbations and asthma worsening in patients with symptomatic asthma despite treatment with inhaled corticosteroids and long‐acting beta2‐agonists [Abstract]. Chest 2013;144(4 Meeting Abstracts):90A.
Vogelberg 2014 {published data only}
    1. Vogelberg C, Engel M, Moroni‐Zentgraf P, Leonaviciute‐Klimantaviciene M, Sigmund R, Downie J, et al. Once‐daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose‐ranging study [Abstract]. Clinical and Translational Allergy 2014;4(Suppl 1):O5.

Additional references

Adams 2008a
    1. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD002738.pub2] - DOI - PMC - PubMed
Adams 2008b
    1. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4] - DOI - PubMed
Allison 2014
    1. Allison DE, Kew KM, Boyter AC. Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD011397] - DOI - PMC - PubMed
Anderson 2005
    1. Anderson HR. Prevalence of asthma. British Medical Journal 2005;330:1037. - PMC - PubMed
Bateman 2004
    1. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline‐defined asthma control be achieved? The gaining optimal asthma control study. American Journal of Respiratory and Critical Care Medicine 2004;170(8):836‐44. - PubMed
Befakadu 2014
    1. Befekadu E, Onofrei C, Colice GL. Tiotropium in asthma: a systematic review. Journal of Asthma and Allergy 2014;7:11‐21. - PMC - PubMed
BNF
    1. Royal Pharmaceutical Society. British National Formulary (online). http://www.medicinescomplete.com. Royal Pharmaceutical Society, (accessed 27 August 2014).
Brozek 2008 [Computer program]
    1. Brozek J, Oxman A, Schünemann H. GradePro Version 3.2 for Windows. Hamilton (Ontario): McMaster University, 2014, 2008.
BTS 2014
    1. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2014;69(Suppl. 1):i1‐i192. - PubMed
Chauhan 2014
    1. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5] - DOI - PMC - PubMed
Chinchilli 2015 [pers comm]
    1. Chinchilli VM. Allocation concealment used in our trial [personal communication]. Email to: D Evans. 16 January 2015.
Chong 2012
    1. Chong J, Karner C, Poole P. Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2] - DOI - PMC - PubMed
Covidence [Computer program]
    1. The Alfred Hospital, Monash University, National ICT Australia and the University of London. Covidence. Melbourne: Alfred Health, 2013.
De Blic 1996
    1. Blic J, Delacourt C, Bourgeois M, Mahut B, Ostinelli J, Caswell C, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double‐blind study. The Journal of Allergy and Clinical Immunology 1996;98(1):14‐20. - PubMed
Ducharme 2008
    1. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] - DOI - PMC - PubMed
Ducharme 2010
    1. Ducharme FM, Ni Choinin M, Greenstone I, Lasserson TJ. Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] - DOI - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
eMC 2014
    1. Electronic Medicines Compendium (eMC). License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014).
GINA 2014
    1. Global Initiative for Asthma. Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014).
Global Asthma Report 2014
    1. International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2014. The Global Asthma Report 2014, http://www.globalasthmareport.org (accessed 28th August 2014).
Gosens 2006
    1. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respiratory Research 2006;7(1):73. - PMC - PubMed
Haahtela 1994
    1. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide inpatients with mild asthma. New England Journal of Medicine 1994;331(11):700‐5. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.
Juniper 1991
    1. Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. The Journal of Allergy and Clinical Immunology 1991;87(2):483‐9. - PubMed
Juniper 2006
    1. Juniper EF, Bousquet J, Abetz L, Bateman ED, GOAL Committee. Identifying 'well‐controlled' and 'not well‐controlled' asthma using the Asthma Control Questionnaire. Respiratory Medicine 2006;100(4):616‐21. - PubMed
Karner 2014
    1. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] - DOI - PMC - PubMed
Kew 2015
    1. Kew KM, Evans DJW, Allison DE, Boyter AC. Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] - DOI - PMC - PubMed
Lipworth 2014
    1. Lipworth BJ. Emerging role of long acting muscarinic antagonists for asthma. British Journal of Clinical Pharmacology 2014;77(1):55‐62. - PMC - PubMed
MECIR 2013
    1. Chandler J, Churchill R, Higgins J, LassersonT, Tovey D. Methodological Expectations for the conduct of Cochrane Intervention Review, version 2.3. http://editorial‐unit.cochrane.org/mecir. (accessed 3rd Feb 2015).
Moulton 2011
    1. Moulton BC, Fryer AD. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. British Journal of Clinical Pharmacology 2011;163(1):44‐52. - PMC - PubMed
Ni 2014
    1. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2] - DOI - PMC - PubMed
NICE 2013
    1. National Institute for Health and Care Excellence. NICE advice [KTT5] High‐dose inhaled corticosteroids in asthma. http://www.nice.org.uk/Advice/ktt5 (accessed 29 August 2014).
NRAD 2014
    1. Royal College of Physicians. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry Report. London: Royal College of Physicians, 2014.
Rashid 2014
    1. Rashid Q, Klein R. Tiotropium in the treatment of patients with asthma. Southern Medical Journal 2014;107(5):330‐7. - PubMed
Reddel 2009
    1. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180(1):59‐99. - PubMed
RevMan [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rodrigo 2015
    1. Rodrigo GJ, Castro‐Rodríguez JA. What is the role of tiotropium in asthma?: A systematic review with meta‐analysis. Chest 2015;147(2):388‐96. - PubMed
Tee 2009
    1. Tee A, Koh MS, Gibson PG, Lasserson TJ, Wilson A, Irving LB. Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001281.pub2] - DOI - PMC - PubMed
Verhamme 2013
    1. Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patient with COPD. European Respiratory Journal 2013;42(3):606‐15. - PubMed
Wise 2013
    1. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat Inhaler and the risk of death in COPD. New England Journal of Medicine 2013;369(16):1491‐501. - PubMed

References to other published versions of this review

Kew 2014
    1. Kew KM, Allison DE, Evans DJW, Boyter AC. Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011437] - DOI - PMC - PubMed

Publication types

MeSH terms